The latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis – Pipeline Review, H2 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.
Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Avail Discount for this report at https://goo.gl/rXEQBo
Myasthenia Gravis Companies Involved in Therapeutics Development
Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alpha Cancer Technologies Inc, Apellis Pharmaceuticals Inc, arGEN-X BV, BioMarin Pharmaceutical Inc, Bristol-Myers Squibb Company, CuraVac Inc, GlaxoSmithKline Plc, Grifols SA, HanAll Biopharma Co Ltd, Millennium Pharmaceuticals Inc, Neurotune AG, Novartis AG, Pfizer Inc, Ra Pharmaceuticals Inc, Regenesance BV, Shire Plc, Toleranzia AB, UCB SA.
Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Purchase the Licensed Report at https://goo.gl/jk3d7M
– The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology).
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on firstname.lastname@example.org with your contact details.